Smith & Nephew PLC ADR SNN

Stock XNYS Rating as of Jun 8, 2026

$30.34 −0.27 (0.88%)

View Full Chart

As of Jun 8, 2026, 8:00:13 PM Delayed Price Closed

Company Report

View Archive

Smith & Nephew Earnings: Sports Medicine Strength Offsets Knee Softness

Debbie S. Wang May 12, 2026

Smith & Nephew saw abbreviated first-quarter results that included underlying revenue growth of 3%, with strong growth in sports medicine/joint repair (up 10%) and arthroscopic-enabling technologies (up 7%).

Read Full Report

Price vs Fair Value

View History

SNN is trading at a 590% premium.

Price

$30.34

Jun 8, 2026

Fair Value

$85.00

Jul 29, 2022

Uncertainty

Medium

1-Star Price: $93.60
5-Star Price: $46.80
Economic Moat: Ltvxwp
Capital Allocation: Nljqplt

Bulls Say, Bears Say

Bulls

Smith & Nephew participates in the fast-growing sports medicine arena, thanks to its extensive arthroscopy portfolio.

Bears

Smith & Nephew's attempted shift to the lower-cost Syncera distribution model in the US was disappointing, which leaves the firm in a tenuous competitive position for large-joint replacement in that market.

Trading Information

Previous Close Price: $30.61
Day Range: $30.33–30.66
52-Week Range: $28.40–38.79
Bid/Ask: $25.75 / $35.05
Shares Outstanding: 424.43M
Market Cap: $12.87B
Volume/Avg: 1M / 1M

Key Statistics

Price/Earnings (Normalized): 14.17
Price/Sales: 2.15
Dividend Yield (Trailing): 2.58%
Dividend Yield (Forward): 2.58%
Total Yield: 6.33%

Company Profile

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Sector: Healthcare
Industry: Medical Devices
Stock Style Box: Mid Core
Total Number of Employees: 16,988
Website: https://www.smith-nephew.com

Competitors

Valuation

Metric	SNN	ZBH	JNJ
Price/Earnings (Normalized)	14.17	10.29	21.64
Price/Book Value	2.44	1.33	6.88
Price/Sales	2.15	2.05	5.87
Price/Cash Flow	11.44	9.19	18.97

Price/Earnings

SNN

ZBH

JNJ

Financial Strength

Metric	SNN	ZBH	JNJ
Quick Ratio	1.40	0.75	0.77
Current Ratio	3.00	1.73	1.03
Interest Coverage	4.46	4.06	24.09

Quick Ratio

SNN

ZBH

JNJ

Profitability

Metric	SNN	ZBH	JNJ
Return on Assets (Normalized)	—	7.33%	13.33%
Return on Equity (Normalized)	—	13.30%	32.77%
Return on Invested Capital (Normalized)	—	9.54%	20.14%

Return on Assets

SNN

ZBH

JNJ

Medical Devices Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Abbott Laboratories ABT	Yknhtvvy	Stdthfn	$158B
Stryker Corp SYK	Vvdnmhxpxq	Mkx	$116B
Medtronic PLC MDT	Ysqtlffj	Jdwbrgl	$104B
Boston Scientific Corp BSX	Vsldrnvg	Skjtzd	$72B
Edwards Lifesciences Corp EW	Slqdkcgs	Dksthm	$49B
DexCom Inc DXCM	Kwtspxmxq	Zrdpf	$30B
GE HealthCare Technologies Inc Common Stock GEHC	Fgghpfvxd	Gqjz	$29B
Koninklijke Philips NV ADR PHG	Hjq	Cgtk	$26B
Steris PLC STE	Bqcvybwr	Sqtjzbg	$20B
Zimmer Biomet Holdings Inc ZBH	Zqwqvlqxt	Jpy	$17B